PCRX
Pacira BioSciences, Inc.
25.20$
+0.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +2.6% | +0.6% | +4.0% | -7.6% | +2.1% | +2.1% | -3.1% | -15.6% | -2.5% | -4.5% | +2.9% | |
| – | +14.0% | +6.5% | +16.4% | +9.1% | +8.0% | +2.0% | -1.9% | -24.5% | -2.6% | -6.0% | +19.5% | |
| – | +54.7% | +20.1% | +34.2% | -0.4% | +12.5% | +2.5% | +5.9% | -50.9% | +7.4% | -9.0% | +42.7% | |
| – | +18.5% | +17.0% | +24.0% | +12.3% | +6.8% | +1.9% | -9.7% | -44.8% | -3.2% | -15.2% | +24.2% | |
| – | +8.9% | -3.7% | +3.1% | -3.9% | +12.6% | -7.6% | +9.2% | +1.0% | +7.4% | +1.3% | +5.4% | |
| – | +8.1% | -7.3% | +6.9% | +8.1% | +12.0% | +6.8% | +10.8% | +6.4% | -3.1% | -1.6% | -10.5% | |
| – | +0.0% | +0.0% | +0.0% | -100.0% | – | – | -5.7% | +0.1% | -0.5% | -2.2% | -0.7% | |
| – | -2.9% | -3.0% | -3.1% | -3.2% | -3.3% | +2.1% | -2.9% | -9.5% | -3.7% | -4.0% | -19.2% | |
| – | +0.2% | -1.9% | +11.1% | +0.6% | +0.4% | +1.7% | -1.1% | -26.8% | +0.3% | -3.0% | +3.1% | |
| – | +4.0% | -4.0% | -0.8% | +230.6% | +1.1% | +1.6% | -0.5% | -65.8% | +12.6% | -9.8% | +12.2% | |
| – | +1.0% | +1.2% | -48.1% | +2,202.5% | +0.0% | +0.4% | +0.2% | -95.4% | +0.9% | -0.2% | +4.9% | |
| – | -4.9% | -42.8% | +108.5% | +3.4% | -1.2% | +21.1% | +30.0% | -41.3% | -14.3% | -7.5% | +25.0% | |
| – | -0.4% | -0.4% | +15.2% | -34.5% | -0.6% | -0.6% | -0.8% | -0.4% | -1.2% | -1.2% | -1.2% | |
| – | +4.6% | +2.5% | -1.4% | -14.8% | +3.8% | +2.6% | -5.1% | -4.0% | -4.7% | -5.7% | +2.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 0.0% | +0.2% | -3.2% | -8.7% | +6.3% | -5.1% | -2.3% | -2.2% | -3.3% | -4.8% | -1.5% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.